Teoh, D., Jia, J., Nixon, A. B., Grace, L., Adams, D. J., Murphy, S. K., & Secord, A. A. (2014). Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

Teoh, Deanna, Jingquan Jia, Andrew B. Nixon, Lisa Grace, David J. Adams, Susan K. Murphy, and Angeles Alvarez Secord. Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression. 2014.

Teoh, Deanna, et al. Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression. 2014.